Scarica l'app Stockscreener
56.60
6.42%
-3.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$60.48
Aprire:
$60.16
Volume 24 ore:
594.92K
Relative Volume:
0.81
Capitalizzazione di mercato:
$2.17B
Reddito:
Utile/perdita netta:
$-241.60M
Rapporto P/E:
-8.5541
EPS:
-6.6167
Flusso di cassa netto:
$-201.34M
1 W Prestazione:
-8.19%
1M Prestazione:
-19.21%
6M Prestazione:
-17.32%
1 anno Prestazione:
-21.35%
Intervallo 1D:
$56.47
$60.48
Intervallo di 1 settimana:
$56.47
$63.50
Portata 52W:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Nome
Disc Medicine Inc
Settore
Industria
Telefono
(617) 674-9274
Indirizzo
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
56.60 | 2.17B | 0 | -241.60M | -201.34M | -6.6167 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Ripresa | Stifel | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-11 | Ripresa | Raymond James | Strong Buy |
| 2025-02-27 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-01 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-17 | Iniziato | Raymond James | Outperform |
| 2023-04-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Iniziato | Stifel | Buy |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2023-03-23 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Disc Medicine Inc Borsa (IRON) Ultime notizie
IRON S-8 & SEC FilingsYahoo Finance - Yahoo! Finance Canada
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Bank of America Corp DE Makes New $9.88 Million Investment in Disc Medicine, Inc. $IRON - marketbeat.com
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine (Nasdaq:IRON)Stock Analysis - Simply Wall Street
Disc Medicine CEO Quisel John D Exercises Options, Holding 262,064 Shares Post-Transaction - Kalkine Media
Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action InvestigationIRON - PR Newswire
Disc Medicine (NASDAQ: IRON) CEO turns 36,000 options into stock - stocktitan.net
IRON Form 4 FilingsDisc Medicine, Inc. SEC Form 4 - stocktitan.net
[Form 4] Disc Medicine, Inc. Insider Trading Activity - stocktitan.net
Kevin Bitterman Sells 27,136 Shares of Disc Medicine (NASDAQ:IRON) Stock - marketbeat.com
Squarepoint Ops LLC Increases Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Disc Medicine (NASDAQ:IRON) Raised to "Hold" at Wall Street Zen - MarketBeat
Officer at Disc Medicine (NASDAQ: IRON) plans to sell 27,136 shares - stocktitan.net
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - PR Newswire
Disc Medicine (NASDAQ:IRON) Shares Down 5%Should You Sell? - MarketBeat
The Technical Signals Behind (IRON) That Institutions Follow - Stock Traders Daily
Opaleye Management Inc. Raises Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones - Benzinga
IRON Reiterated by Wedbush -- Price Target Maintained at $100 - GuruFocus
Disc Medicine's Phase 2 rare blood cancer data; Frazier adds to public fund - Endpoints News
Form 8K Disc Medicine Inc For: 10 September By Investing.com - Investing.com South Africa
Disc Medicine reports promising DISC-3405 Phase 2 data - TipRanks
Disc Medicine's (IRON) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Form 8K Disc Medicine Inc For: 10 September By Investing.com - Investing.com Canada
Disc Medicine at Wells Fargo conference: two drug bets near key tests - Investing.com Canada
Form 8K Disc Medicine Inc For: 10 September By Investing.com - Investing.com India
Form 8K Disc Medicine Inc For: 10 September By Investing.com - Investing.com UK
H.C. Wainwright reiterates Disc Medicine stock rating on trial data By Investing.com - Investing.com India
H.C. Wainwright reiterates Disc Medicine stock rating on trial data By Investing.com - Investing.com Canada
Disc Medicine reports Phase 2 DISC-3405 trial results - grafa.com
Jefferies reiterates Disc Medicine stock rating on polycythemia data By Investing.com - Investing.com Nigeria
Jefferies reiterates Disc Medicine stock rating on polycythemia data By Investing.com - Investing.com Canada
Disc Medicine stock rating held at Outperform by BMO on trial data - Investing.com Canada
Disc Medicine reports positive phase 2 trial results for DISC-3405 By Investing.com - Investing.com South Africa
Disc Medicine (IRON) Reports Promising Phase 2 Data; Market Pric - GuruFocus
Disc Medicine reports positive phase 2 trial results for DISC-3405 - investing.com
Disc Medicine reports positive phase 2 trial results for DISC-3405 By Investing.com - Investing.com Australia
Disc Medicine reports positive phase 2 trial results for DISC-3405 By Investing.com - Investing.com Nigeria
Disc Medicine reports positive phase 2 trial results for DISC-3405 By Investing.com - Investing.com Canada
Disc Medicine Reports Positive Initial RESTORE-PV Results for DISC-3405 in Polycythemia Vera - Quiver Quantitative
Blood-removal procedures fell from 4.0 at baseline to 0.6 after treatment - Stock Titan
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $135,052.44 in Stock - MarketBeat
Disc Medicine (NASDAQ: IRON) director sells shares under preset plan - stocktitan.net
Disc Medicine at cantorfitzgerald healthcare conference: pipeline nears key tests - Investing.com Canada
Disc Medicine faces class action over alleged m... - Pluang
Legal & General Group Plc Invests $1.35 Million in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Inc Azioni (IRON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Disc Medicine Inc Azioni (IRON) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bitterman Kevin | Director |
Sep 11 '26 |
Sale |
70.11 |
27,136 |
1,902,505 |
0 |
| Bitterman Kevin | Director |
Sep 11 '26 |
Option Exercise |
45.07 |
27,136 |
1,223,144 |
27,136 |
| KEVIN J BITTERMAN | Officer |
Sep 11 '26 |
Proposed Sale |
70.11 |
27,136 |
1,902,505 |
0 |
| Atlas Venture Opportunity Fund | Shareholder |
Sep 04 '26 |
Proposed Sale |
79.37 |
759 |
60,242 |
0 |
| Atlas Venture Opportunity Fund | Shareholder |
Sep 04 '26 |
Proposed Sale |
79.37 |
912 |
72,385 |
0 |
| Atlas Venture Fund X, LP | Shareholder |
Sep 04 '26 |
Proposed Sale |
79.37 |
2,212 |
175,566 |
0 |
| Bitterman Kevin | Director |
Sep 04 '26 |
Sale |
79.96 |
1,689 |
135,052 |
13,427 |
| Atlas Venture Fund XII, LP | Shareholder |
Sep 04 '26 |
Proposed Sale |
79.37 |
18 |
1,429 |
0 |
| Atlas Venture Fund XII, LP | Shareholder |
Sep 03 '26 |
Proposed Sale |
80.05 |
54 |
4,323 |
0 |
| Bitterman Kevin | Director |
Sep 03 '26 |
Sale |
79.98 |
5,203 |
416,136 |
13,445 |
1.15%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):